Connection

Andrew Kraft to Macrolides

This is a "connection" page, showing publications Andrew Kraft has written about Macrolides.
Connection Strength

0.372
  1. Treatment of patients with metastatic melanoma with bryostatin-1--a phase II study. Melanoma Res. 1999 Dec; 9(6):599-606.
    View in: PubMed
    Score: 0.043
  2. Biological activity of 26-succinylbryostatin 1. Biochim Biophys Acta. 1996 Jul 24; 1312(3):197-206.
    View in: PubMed
    Score: 0.034
  3. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. Cancer Res. 1996 Feb 15; 56(4):802-8.
    View in: PubMed
    Score: 0.033
  4. Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2. Cancer Res. 1995 Sep 01; 55(17):3716-20.
    View in: PubMed
    Score: 0.032
  5. Regulation of AP-3 enhancer activity during hematopoietic differentiation. J Cell Physiol. 1995 Jul; 164(1):26-34.
    View in: PubMed
    Score: 0.032
  6. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. Cancer Res. 1993 Jun 15; 53(12):2810-5.
    View in: PubMed
    Score: 0.028
  7. In vivo administration of bryostatin 1, a protein kinase C activator, decreases murine resistance to Salmonella typhimurium. Cancer Res. 1992 Apr 15; 52(8):2143-7.
    View in: PubMed
    Score: 0.025
  8. Bryostatin 1: a potential anti-leukemic agent for chronic myelomonocytic leukemia. Leukemia. 1991 Apr; 5(4):283-7.
    View in: PubMed
    Score: 0.024
  9. Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin. Cancer Res. 1990 Sep 01; 50(17):5520-5.
    View in: PubMed
    Score: 0.023
  10. Overexpression of protein kinase C beta 1 is not sufficient to induce factor independence in the interleukin-3-dependent myeloid cell line FDC-P1. Oncogene. 1990 Aug; 5(8):1243-6.
    View in: PubMed
    Score: 0.023
  11. Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res. 1989 Mar 01; 49(5):1287-93.
    View in: PubMed
    Score: 0.020
  12. Bryostatin induces changes in protein kinase C location and activity without altering c-myc gene expression in human promyelocytic leukemia cells (HL-60). Oncogene. 1987 May; 1(2):111-8.
    View in: PubMed
    Score: 0.018
  13. Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc Natl Acad Sci U S A. 1986 Mar; 83(5):1334-8.
    View in: PubMed
    Score: 0.017
  14. A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study. Clin Cancer Res. 1999 Sep; 5(9):2344-8.
    View in: PubMed
    Score: 0.011
  15. Interleukin-3 and bryostatin 1 mediate rapid nuclear envelope protein phosphorylation in growth factor-dependent FDC-P1 hematopoietic cells. A possible role for nuclear protein kinase C. J Biol Chem. 1989 Dec 25; 264(36):21896-901.
    View in: PubMed
    Score: 0.005
  16. Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells. Proc Natl Acad Sci U S A. 1987 Dec; 84(23):8483-7.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.